[go: up one dir, main page]

SK30396A3 - Beads, method for producing them and a pharmaceutical preparation containing the same - Google Patents

Beads, method for producing them and a pharmaceutical preparation containing the same Download PDF

Info

Publication number
SK30396A3
SK30396A3 SK303-96A SK30396A SK30396A3 SK 30396 A3 SK30396 A3 SK 30396A3 SK 30396 A SK30396 A SK 30396A SK 30396 A3 SK30396 A3 SK 30396A3
Authority
SK
Slovakia
Prior art keywords
active ingredient
hydrophilic polymer
controlled release
core
pharmaceutical composition
Prior art date
Application number
SK303-96A
Other languages
English (en)
Slovak (sk)
Inventor
Lars Stubberud
Hans Arwidsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of SK30396A3 publication Critical patent/SK30396A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK303-96A 1994-07-08 1995-06-07 Beads, method for producing them and a pharmaceutical preparation containing the same SK30396A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402422A SE9402422D0 (sv) 1994-07-08 1994-07-08 New beads for controlled release and a pharmaceutical preparation containing the same
PCT/SE1995/000676 WO1996001621A1 (en) 1994-07-08 1995-06-07 New beads for controlled release and a pharmaceutical preparation containing the same

Publications (1)

Publication Number Publication Date
SK30396A3 true SK30396A3 (en) 1997-09-10

Family

ID=20394677

Family Applications (1)

Application Number Title Priority Date Filing Date
SK303-96A SK30396A3 (en) 1994-07-08 1995-06-07 Beads, method for producing them and a pharmaceutical preparation containing the same

Country Status (23)

Country Link
US (1) US5783215A (et)
EP (1) EP0723434A1 (et)
JP (1) JPH09502738A (et)
CN (1) CN1134108A (et)
AU (1) AU700949B2 (et)
BR (1) BR9506026A (et)
CA (1) CA2170526A1 (et)
CZ (1) CZ73196A3 (et)
EE (1) EE03280B1 (et)
FI (1) FI961056L (et)
HU (1) HUT75772A (et)
IL (1) IL114448A (et)
MX (1) MX9600858A (et)
NO (1) NO960837L (et)
NZ (1) NZ289947A (et)
PL (1) PL313386A1 (et)
RU (1) RU2141822C1 (et)
SE (1) SE9402422D0 (et)
SK (1) SK30396A3 (et)
TR (1) TR199500822A2 (et)
TW (1) TW460300B (et)
WO (1) WO1996001621A1 (et)
ZA (1) ZA955545B (et)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
CO5070568A1 (es) 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
KR100838930B1 (ko) 1999-11-11 2008-06-16 화이자 헬스 에이비 톨테로딘을 포함하는 약학 제제 및 이의 용도
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2002358270A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US20060257482A1 (en) * 2002-06-07 2006-11-16 Patrik Kumar Modified release, multiple unit drug delivery systems
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
WO2004072061A1 (en) 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8734850B2 (en) 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
RU2261095C1 (ru) * 2004-01-09 2005-09-27 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая нестероидным противовоспалительным действием, и способ ее изготовления
EP1753405A4 (en) * 2004-06-10 2008-09-17 Glatt Air Tech Inc SLOW RELEASE PHARMACEUTICAL PREPARATION
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2007016948A1 (de) 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
PL1842534T3 (pl) * 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
LT2679228T (lt) 2006-06-21 2018-05-10 Opko Ireland Global Holdings, Ltd. Terapija naudojant vitamino d atstatymo agentą ir vitamino d hormoninį pakaitinį agentą
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148683A4 (en) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc SAFE AND EFFECTIVE METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDIA IN CHRONIC RENAL DISEASES
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
JP2012500823A (ja) * 2008-08-29 2012-01-12 グラクソ グループ リミテッド １−イソプロピル−４−｛［４−（テトラヒドロ−２ｈ−ピラン−４−イルオキシ）フェニル］カルボニル｝ヘキサヒドロ−１ｈ−１，４−ジアゼピンまたはその塩を含んでなる剤形
CA2769760A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US20140112995A1 (en) * 2009-07-31 2014-04-24 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
EP3636280B1 (en) 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6855387B2 (ja) * 2015-12-28 2021-04-07 エスエス製薬株式会社 圧縮成型製剤
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108272766B (zh) * 2018-03-21 2020-07-07 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
FR2610327B1 (fr) * 1987-01-30 1989-08-25 Charbonnages Ste Chimique Interpolymere composite a plusieurs couches, son procede de preparation, son application au renforcement de matrices thermoplastiques rigides et compositions renforcees correspondantes
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.

Also Published As

Publication number Publication date
CZ73196A3 (en) 1996-08-14
MX9600858A (es) 1997-06-28
TR199500822A2 (tr) 1996-06-21
IL114448A0 (en) 1995-11-27
NO960837D0 (no) 1996-02-29
HU9600575D0 (en) 1996-07-29
EP0723434A1 (en) 1996-07-31
SE9402422D0 (sv) 1994-07-08
IL114448A (en) 1999-09-22
NO960837L (no) 1996-02-29
EE03280B1 (et) 2000-08-15
CA2170526A1 (en) 1996-01-25
HUT75772A (en) 1997-05-28
WO1996001621A1 (en) 1996-01-25
US5783215A (en) 1998-07-21
JPH09502738A (ja) 1997-03-18
AU700949B2 (en) 1999-01-14
BR9506026A (pt) 1997-10-14
NZ289947A (en) 1998-07-28
CN1134108A (zh) 1996-10-23
FI961056A7 (fi) 1996-05-06
ZA955545B (en) 1996-01-08
TW460300B (en) 2001-10-21
FI961056L (fi) 1996-05-06
FI961056A0 (fi) 1996-03-07
RU2141822C1 (ru) 1999-11-27
PL313386A1 (en) 1996-06-24
AU2993695A (en) 1996-02-09

Similar Documents

Publication Publication Date Title
SK30396A3 (en) Beads, method for producing them and a pharmaceutical preparation containing the same
FI97686B (fi) Menetelmä helmien valmistamiseksi tarkoituksena tuottaa hallitusti vapauttavia tuotteita
KR100794402B1 (ko) 적어도 시한 펄스를 일으키는 제어 방출을 위한 제약 투여형
AU775914B2 (en) Controlled release galantamine composition
EP1416920B1 (en) Multiplex drug delivery system suitable for oral administration
RU2385712C2 (ru) Рецептура с контролируемым высвобождением
CA2342340C (en) New sustained release oral formulations
CA2344372C (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
KR20000071247A (ko) 활성 물질이 조절 방출되는 오피오이드 진통제
CZ303943B6 (cs) Vícevrstvá tableta s rízeným uvolnováním aktivní látky
WO2004064815A1 (en) Oral dosage formulation
WO2014028878A1 (en) Pharmaceutical compositions of memantine
SK4822000A3 (en) MONOLITHIC SYSTEM CONTAINING ONE OR MORE DRUGS, CONSISTING OFì (54) THREE LAYERS WITH DIFFERENT RELEASE MECHANISMS
MXPA06008854A (es) Mini tabletas de clorhidrato de venlafaxina de liberacion prolongada recubiertas.
CA2379595A1 (en) Oral controlled release formulations
MX2008016565A (es) Composiciones farmaceuticas que comprenden una combinacion de piperidinoalcanol y descongestivo.
WO2006045152A1 (en) Improved tabletting process
RU2411035C2 (ru) Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината
JP3343144B2 (ja) マイクロカプセル
KR20090128918A (ko) 염산 알푸조신이 함유된 서방형 제제의 제조
HK1149482A (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
HK1107780B (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
HK1148676A (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
HK1107780A1 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride